glp 1 agonist parkinson Are we measuring the wrong primary outcome for GLP-1 drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep The glucagon-like peptide 1 (GLP)

Book your IV therapy at a location near you and start feeling your best today

The clinical data reflects this: a 2022 retrospective analysis of 340 patients receiving lipotropic injections as part of a medically-supervised weight loss program found that those who maintained a 500-calorie daily deficit lost an average of 8.4% body weight over 16 weeks, compared to 5.1% in matched controls on caloric restriction alone

Therefore, monitoring of the platelet count and serum potassium concentrations are recommended during therapy

Unlike milk thistle, which you must ingest, your body actually manufactures its own glutathione in almost every cell, with the highest concentrations found in the liver

2019;24(3):491e50421